Actuate Therapeutics Inc (ACTU) Stock Forecast & Price Target

Actuate Therapeutics Inc (ACTU) has an ST Score of 30.4 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate ACTU a Buy, with a price target of $21.00 (+3287.1% vs the current price). Our ST Score grades it C- (30.4/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C, Profitability F, Financial Strength D-, Momentum D-, Growth C+, Forecast A.

Actuate Therapeutics Inc (ACTU) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Actuate Therapeutics Inc (ACTU) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Actuate Therapeutics Inc (ACTU) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Actuate Therapeutics Inc (ACTU) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Actuate Therapeutics Inc (ACTU) is $21.00 from 1 analysts, which is +3287.1% versus the recent price of $0.62.

Actuate Therapeutics Inc (ACTU) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.